Thus, the analysis of primary prostate cancer samples, as well as studies on tumor organoids, provided no evidence that ERG is an effector of SPOP mutation in human prostate cancer and indicates that SPOP mutations activate an oncogenic program leading to prostate cancer independently on ERG stabilization/activation [134]. The gene discussed is SPOP; the disease is prostate cancer.